Biomea Fusion (BMEA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BMEA Biomea Fusion

Watchlist

9.370
-0.970-9.38%

Close Oct 31 16:00 ET

10.188
+0.818+8.73%

Post 20:01 ET

339.56MMarket Cap-2336P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $41
Moomoo NewsOct 31 09:31 ET · Ratings
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $19 to $60
Moomoo NewsOct 31 09:00 ET · Ratings
Express News | Biomea Fusion Inc - Preclinical Data Shows Bmf-219 Enhanced Effectiveness of GLP-1-Based Therapies
ReutersOct 30 16:02 ET
Express News | Biomea Fusion Inc - Phase II Study (Covalent-211), Combining Icovamenib With a GLP-1-Based Therapy, Planned to Begin in 2025
ReutersOct 30 16:00 ET
Biomea Fusion Shares Are Trading Lower. The Company Reported Q3 Financial Results.
BenzingaOct 30 15:08 ET
Biomea Fusion Is Maintained at Equal-Weight by Barclays
Dow JonesOct 30 10:47 ET · Ratings

Comments

Kraks

9 hours ago

No flooring so far

$Biomea Fusion (BMEA.US)$ seems to aim at 9 or below...

Trytosaveabit

Yesterday 04:04

Update

$Biomea Fusion (BMEA.US)$ Reuters· 1 min ago
Biomea Fusion Inc - Preclinical Data Shows Bmf-219 Enhanced Effectiveness of GLP-1-Based Therapies

Teddy123

Oct 29 23:02

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

$Biomea Fusion (BMEA.US)$
REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate hig...